Cystetic Medicines

Executive Summary

Cystetic Medicines is a private biotechnology company founded in 2021 and headquartered in Cambridge, Massachusetts. The company is developing a novel class of inhaled small-molecule therapies for cystic fibrosis (CF) and other genetic diseases, leveraging its proprietary 'molecular prosthetics' platform. This platform aims to restore function to defective CFTR proteins, particularly for the approximately 10% of CF patients who have mutations that produce little-to-no CFTR protein and are therefore ineligible for existing modulator therapies. By addressing this significant unmet need, Cystetic Medicines could expand treatment options to a previously underserved patient population. The company's focus on inhaled delivery may enhance lung-specific efficacy and reduce systemic side effects. While still in early-stage development, Cystetic Medicines has the potential to transform the CF treatment landscape if its platform proves successful. The company's progress toward clinical development will be closely watched, as it targets a critical gap in CF therapy. With a strong scientific foundation and a clear patient need, Cystetic Medicines represents a promising opportunity in the precision medicine space for genetic diseases.

Upcoming Catalysts (preview)

• H2 2026Series A Financing Announcement70% success
• 2027IND Submission for Lead CFTR Prosthetic Candidate60% success
• H1 2027Preclinical Efficacy Data Presentation75% success